Showing 1–12 of 15 resultsSorted by latest
Healthcare & Life Sciences
The global pharmaceutical industry is entering a pivotal period marked by rapid scientific advancement, evolving healthcare demands, and substantial market transformation. Innovation remains the core engine of growth, particularly in biologics, biosimilars, oncology, immunology, and metabolic disorders.
This report is your 2026 Wishlist. These 15 stocks are not just opportunistic trades; they are high conviction “gifts” that we believe are currently mispriced relative to their 2026 earnings potential
Novartis agreed to acquire Avidity for $72.00 per share in cash, valuing the company at about $12 billion on a fully diluted basis and roughly $11 billion enterprise value at expected close. The price reflects a 46% premium to Avidity’s October 24, 2025 close and 62% to the 30-day VWAP, with closing targeted for H1 2026 subject to regulatory approvals, shareholder vote, and completion of a cardiology SpinCo separation.
Metsera, Inc. is a clinical-stage biopharmaceutical company developing next generation medicines for obesity and metabolic diseases, with the aim of reducing the physical, emotional, and economic burden of these conditions.
Large Language Models (LLMs) are sophisticated artificial intelligence systems designed to understand and generate human-like text based on vast amounts of training data.
MedTech includes technologies like pacemakers, insulin pumps, MRI machines, and wearable devices that improve healthcare by enhancing diagnosis, treatment, and patient care. These technologies boost safety, efficiency, and patient control.
The global pharmaceutical manufacturing market is valued at USD 576.54 billion in 2024 and is expected to grow to USD 1,905.76 billion by 2034, with a 12.7% annual growth rate. This growth is mainly driven by increased demand for biopharmaceuticals and new drug production technologies.
Artificial intelligence (AI) is reshaping the pharmaceutical industry in 2024, driving transformative advancements in drug discovery, development, and delivery.
The medical device industry in 2024 showcased an impressive trajectory of growth, propelled by a confluence of demographic, technological, and economic factors.
The medical device sector is also paying greater attention to patient-centric design principles, sustainability practices and navigating an increasingly complex regulatory environment focused on safety, efficacy and ethical product development. Companies able to balance these dynamics through agile innovation, prudent financial management and sound regulatory strategies are best primed for market leadership.
The global pharmaceutical and biotechnology (pharma & biotech) industry showed remarkable resilience in 2023, recovering strongly from the temporary slowdown caused by the COVID-19 pandemic.
The adoption of new treatments remains a key driver of growth in the pharmaceutical market. However, the industry faces challenges such as patent lifecycles and increasing competition from generic and biosimilar drugs. These factors will continue to influence medicine spending and overall market growth.